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Paraquat-induced nephrotoxicity involves severe renal damage caused by reactive oxygen species (ROS), 
specifically by increasing superoxide (O2
●-
) generation in the kidney. While proven to be of benefit in animal 
models of organ injury involving O2
●-
, superoxide dismutase (SOD) and superoxide dismutase mimetics 
(SODm) can suffer problems regarding their bioavailability and toxicity. Since ROS has been incriminated in 
the pathogenesis of several disease conditions including acute kidney injury, the search for ideal SODm 
therefore continues unabated. Thus, the current study aims at investigating the therapeutic potential of 
Manganese (II) complexes of ethylenebis (oxyethylenenitrilo) tetraacetic acid (EGTA) and ethylenebis 
hydroxyphenylglycine (EHPG), novel SODm, against paraquat-induced nephrotoxicity using an in vivo 
rodent model. Administration of a single intraperitoneal dose of 10-50 or 100 mg/kg paraquat  to male Wistar 
rats (200-250g) produced acute kidney injury within 48 and 24 hours respectively; as evidenced by a 
significant increase in serum creatinine, fractional excretion of sodium and a reduction in creatinine 
clearance. Unlike Mn (II)-EGTA (2mg/kg), Mn (II)-EHPG (4mg/kg) was able to significantly attenuate the 
acute kidney injury induced by 10-50 mg/kg paraquat. These complexes were not toxic at the doses 
examined unlike SOD or conventional SODm which can display pro-oxidant actions at higher 
concentrations. Since the clinical toxicity profiles of EGTA and EHPG are already known, these novel SODm 
particularly Mn (II)-EHPG could be beneficial in attenuating disease conditions involving ROS generation.  
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INTRODUCTION 
Paraquat (1,1’-dimethyl-4,4’-bipyridium dichloride, 
also known as methyl viologen), is a widely used 
broad-spectrum, fast acting herbicide; which is 
extremely toxic, causing fatalities due to 
accidental or intentional poisoning prevalently in 
developing countries (Gunnell and Eddleston, 
2003; Eddleston and Phillips, 2004). Paraquat 
poisoning causes severe multiple organ failure, 
with the degree of poisoning dependant on the 
route of administration, the amount administered 
and duration of exposure. It is rapidly distributed 
within the body with highest concentrations 
accumulating within the kidneys where it 
produces early and severe nephrotoxicity (Rose 
and Smith, 1977). Additionally, as it is primarily 
excreted unchanged via the kidneys, the 
consequent reduction in renal function increases 
plasma concentrations by up to 5-fold which 
contributes to paraquat toxicity in other organs; 
especially the lungs (Hawksworth et al., 1981; 
Smith, 1987). Ultimately, respiratory failure, in the 
presence of nephrotoxic acute renal failure (ARF), 
is responsible for most deaths caused by 
paraquat (Smith, 1987; Haley, 1979; Nagata et 
al., 1992).  
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Therefore, maintaining renal function in patients 
suffering from paraquat poisoning remains a 
therapeutically important treatment strategy. The 
role of superoxide anions (O2
●-
) in the 
pathogenesis of paraquat toxicity has prompted 
much interest in the development of safe and 
effective antioxidants to negate its injurious 
effects (Suntres, 2002). Unfortunately, native 
superoxide dismutase (SOD) cannot be used 
effectively due to recognised problems with its 
short half-life, poor bioavailability and 
immunogenicity (Freeman et al., 1985; 
Muzykantov, 2001; Muscoli et al., 2003). 
Furthermore, SOD can have pro-oxidant activities 
at higher concentrations, e.g. Cu/Zn-SOD can 
promote the generation of hydroxyl radicals (Mao 
et al., 1993; Jewett et al., 1999) and inhibit the 
ability of superoxide to regulate lipid peroxidation 
(McCord and Edeas, 2005; Nelson et al., 1994). 
This has generated much interest in SOD 
mimetics, leading to the development of agents 
including macrocyclics, manganese salens, 
nitroxides, porphyrins and many other catalytic 
antioxidants (Muscoli et al., 2003; Salvemini et al., 
2002; Mitchell et al., 1990; Cuzzocrea et al., 
2001; Spasojevic et al., 2001; Batinic-Haberle, 
2002; Sharpe et al., 2002; Fisher et al., 2003). 
However, many of these have also suffered 
problems ranging from cytotoxicity to poor stability 
(Liu et al., 1994; Collman et al., 2004). 
Furthermore, in common with native SOD, higher 
concentrations of some of these SOD mimetics 
can have pro-oxidant actions (Paller and Eaton, 
1995; Czapski et al., 2002; McCord and Edeas, 
2005). 
 
Recently, the observation that complexes formed 
between metal ions and the common chelator 
sodium edentate or ethylenediaminetetraacetic 
acid (EDTA) possess significant SOD and 
catalase mimetic properties (Fisher et al., 2004a) 
prompted investigation of the SOD and catalase 
activities of other commonly used chelators and 
their metal complexes. Low concentrations of the 
calcium ion chelator ethylenebis 
(oxyethylenenitrilo) tetraacetic acid (EGTA) have 
been shown to solubilise amyloid plaques in post-
mortem brain samples from patients suffering 
from Alzheimer’s disease and to reduce nitric 
oxide (NO)-induced calcium influx into endothelial 
cells and prevent consequent cell death (Cherny 
et al., 1999; David-Dufilho et al., 2001). Some of 
these beneficial effects of EGTA have been 
credited to its ability to bind the excess copper  
(II) (Cu
2+
) ions, which contribute, to disease 
pathology; however, it is now also clear that 
complexing EGTA with Cu (II) or Mn (II) promotes 
significant SOD activity (Fisher et al., 2004b). In 
addition, the related chelating agent ethylenebis 
hydroxyphenylglycine (EHPG), which is used as a 
contrast agent for magnetic resonance imaging 
and as a transferring mimic in the study of 
manganese transport (Richardson et al., 1999; 
Bihari et al., 2002), has also been shown to 
exhibit significant SOD activity when complexed 
with Mn (II) or Cu (II) (Fisher et al., 2004b).  
 
We have previously demonstrated that Mn (II) 
complexes of EGTA and EHPG are beneficial in 
reducing paraquat-mediated cellular injury and 
death of confluent NRK-52E cells (renal cell line) 
in culture by attenuating paraquat-mediated 
increase in superoxide anion and hydroxyl radical 
generation (Samai et al., 2008). The current study 
was therefore conducted with the aim of 
investigating whether these complexes could 
produce similar beneficial effect in an in vivo 
rodent model of paraquat nephrotoxicity. 
 
MATERIALS AND METHODS 
Chemicals 
Unless otherwise stated, all compounds used in 
this study were purchased from Sigma-Aldrich 
Company Ltd. (Poole, Dorset, UK). Mn (II) 
complexes of EGTA and EHPG were kindly 
synthesized as described previously (Fisher et al., 
2004b) and provided by Dr Theresa Hague and 
Professor Declan Naughton, Biomedical & 
Pharmaceutical Sciences Research Group, 




A total of one hundred and eight (108) male wistar 
rats (weighing 200-250 g) purchased from 
Charles River laboratories (Margate, UK) were 
used. These animals were allowed free access to 
a certified rodent diet (expanded pellets R & M 
no. 3) from special diet services and water 
throughout the experimental period. They were all 
housed in a room kept at a temperature of 19 ± 2 
0
c and relative humidity of 46–55 % and were 
maintained on a light/dark cycle of 12 hours/12 
hours and were recruited into the study a week 
after delivery. The animals were handled and 
treated in accordance with the British Home 
Office Animals (Scientific Procedures) Act 1986 
and the University of Brighton Local Ethical and 
Health Safety Regulations.  
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The experimental protocol was approved by the 
University of Brighton Ethics Committee and was 
performed under British Home Office Project 
License 70/6553.   
 
Characterization of Rodent Model of Paraquat-
induced Acute Kidney Injury (AKI) 
The rats were randomly allocated into two groups 
for the characterization of paraquat-mediated 
acute kidney injury (AKI). In the first group (the 
paraquat treated group), paraquat dissolved in 
normal saline was administered intraperitoneally 
as a single dose to five subgroups at a dose of 
2.5, 5, 10, 50 and 100 mg/kg respectively. An 
equal volume of the vehicle (normal saline) was 
administered intraperitoneally to the second group 
to serve as control. The doses of paraquat were 
based on previously published work in which the 
effects of paraquat on gene expression in the 
kidney was investigated in male Wistar rats 
(Tomita et al., 2006).  
  
Following the injections, the rats were housed 
separately in metabolism cages for the daily 
collection of urine. During the treatment period the 
rats were observed for features of paraquat 
toxicity such as bleeding and respiratory distress. 
At the end of the experimental period, usually 48 
hours, except for rats treated with 100 mg/kg 
paraquat, which was 24 hours, the rats were 
terminally anaesthetized with intraperitoneal 
pentobarbital (50 mg/kg) and placed on a 
temperature-regulated table to maintain their body 
temperature (37 
0
c). The abdominal cavity was 
exposed via a high mid-line incision and a total 
bilateral nephrectomy was performed. The kidney 
capsule was removed and the kidneys were kept 
in formaldehyde for histopathological 
examination.  
 
In addition, blood samples were obtained by 
cardiac puncture and the rats were subsequently 
sacrificed. Serum was collected following 
centrifugation of the blood samples at 13000 rpm 
for 5 minutes. The serum and urine samples were 
subsequently used for biochemical analysis for 
markers of AKI (specifically creatinine). In 
addition, the urine samples were qualitatively 
analysed for protein, blood and glucose using 
urine dipsticks. Furthermore, serum and urinary 
sodium concentrations were evaluated via flame 
photometry with the subsequent calculation of 
fractional excretion of sodium (FENa) and 
creatinine clearance. 
Intervention against Paraquat-induced AKI 
We have previously shown that Mn (II) complexes 
of EHPG and EGTA are efficacious in protecting 
against paraquat-mediated renal cytotoxicity of 
confluent NRK-52E cells in vitro (Samai et al., 
2008). Thus, the hypothesis that these novel SOD 
mimetics could also protect against paraquat -
induced nephrotoxicity (specifically AKI) in an in 
vivo rodent model was tested. For this model, the 
rats were randomly allocated into six initial 
groups. The first, second, third and fourth group 
of rats were exclusively treated with a single 
intraperitoneal dose of normal saline, paraquat 
only (10 mg/kg), Mn (II)-EGTA only (2 mg/kg), 
and Mn (II)-EHPG only (4 mg/kg) respectively. A 
single dose of paraquat (10 mg/kg) was also co-
administered with either Mn (II)-EHPG (4mg/kg) 
or Mn (II)-EGTA (2mg/kg) intraperitoneally into 
fifth and sixth group of rats respectively. The 
results of the initial intervention study indicated 
that Mn (II)-EHPG at the dose examined 
completely reversed the nephrotoxic effect 
produced by 10 mg/kg paraquat whilst Mn (II)-
EGTA did not offer any protection. Thus, the 
ability of Mn (II)-EHPG (4mg/kg) to protect against 
the nephrotoxic effect of 50 mg/kg paraquat was 
further investigated. For this experiment the rats 
were randomly allocated into four groups 
comprising of control (normal saline only), Mn (II)-
EHPG only (4 mg/kg), paraquat only (50 mg/kg), 
and paraquat (50 mg/kg) plus Mn (II)-EHPG (4 
mg/kg) treated groups. At the end of the 
experimental period (48 hours), the animals were 
treated as described above. Creatinine and 
sodium concentrations were subsequently 
determined in the serum and urine samples; with 
urinalysis performed for proteins, blood and 
glucose. Finally, creatinine clearance and FENa 
were evaluated.   
 
Measurement of Serum and Urinary Creatinine 
Serum and urinary creatinine levels were 
evaluated using the recently characterized 
method of Piero et al. (1988), which is a 
colorimetric assay based on the measurement of 
hydrogen peroxide. 
 
Measurement of Creatinine Clearance and 
Fractional Excretion of Sodium 
All the urine passed in a 24-hour period was 
collected and one sample of blood was taken 
during the day of collection. 
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The creatinine clearance was computed in 
mL/min from the product of the total urinary 
creatinine (µmol/L) and the urine flow (mL/min) 
divided by the serum creatinine (µmol/L). FENa is 
not a test, but rather a calculation based on the 
concentrations of sodium and creatinine in the 
blood and urine (as shown below). Serum and 
urinary sodium concentrations were measured by 










Results are expressed as mean ± SEM. Means 
were obtained from multiple experiments 
performed in triplicate. Data were analyzed with 
the commercially available statistical software 
(Graphpad Prism, version 3.0, Graphpad 
software, San Diego, CA, USA). Differences 
between mean values within the groups were 
determined using Student’s t-test and one way 
analysis of variance (ANOVA) followed by a 
Dunnett’s test for comparison of multiple means. 




Administration of 100 mg/kg dose of paraquat 
intraperitoneally to a subgroup of rats resulted in 
severe intercoastal recession, nasal flaring and 
respiratory distress, including bleeding from the 
nostrils, eyes, and mouth, with spastic paralysis of 
the hind limbs, polyuria, haematuria, glycosuria 
and proteinuria within the first 24 hours. These 
rats were euthanized after 24 hours to reduce 
pain and distress. The subgroup of rats which 
received 50 mg/kg paraquat also manifested 
polyuria within the first 24 hours. However, 
proteinuria, haematuria, glycosuria and a 
significant reduction in urine production with 
moderate to severe respiratory distress, were only 
noted in this subgroup of rats by the end of 48 
hours as compared to the control group; with 
some manifesting anuria. Thus, the 48 hour time 
point was used as the hallmark for the onset of 
the paraquat -induced AKI. In contrast, there were 
no apparent differences between the physical 
features and the urinalysis profile of the control 




Table 1: Some Physical Features and Urinary Profile of the Paraquat Treated Subgroup of Rats. 
 
Treatment group  Respiratory 
distress 
Spastic paralysis 
of hind limbs 
Proteinuria Haematuria Glycosuria 
Control  
(0 mg/kg paraquat) 
- - - - - 
2.5 mg/kg paraquat - - - - - 
5.0 mg/kg paraquat - - - - - 
10 mg/kg paraquat - - - - - 
50 mg/kg paraquat +++ +++ ++ ++ ++ 
100 mg/kg 
paraquat 
++++++ ++++++ ++++ ++++ ++++ 
 
: “+” indicates the presence of a symptom and the number of pluses indicates the intensity of the symptom and “–“indicates the 
absence of the symptom. 
 
Significant elevation of serum creatinine levels 
from baseline control values was used as a 
biochemical marker of AKI. AKI was noted in rats 
within 24 and 48 hours following single 
intraperitoneal administration of 100 and 10-50 
mg/kg dose of paraquat respectively. A significant 
increase in the concentrations of serum creatinine 
by 2.7, 3.6 and 4.4 fold and FENa by 8, 13, and 29 
fold was noted in rats treated with 10, 50, and 100 
mg/kg paraquat respectively as compared to the 
control group (P< 0.05). This was concurrently 
accompanied by a significant reduction in 
creatinine clearance by 95% in all three paraquat 
treated subgroups (P< 0.05; Figure1 (A-C).  
 
In the absence of either Mn (II)-EGTA or Mn (II)-
EHPG, the 10 mg/kg dose of paraquat 
significantly increased the serum creatinine levels 
and FENa by 2 and 11 fold respectively with a 
significant reduction of 84 % in creatinine 
clearance when compared to the control group 
(P< 0.05).  
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FENa = UNa x PCr  x 100% 
PNa x UCr 
 
Where UNa and PNa represent urinary and 
serum sodium and PCr and UCr serum and 
urinary creatinine respectively. 
 
In contrast, there were no significant differences 
in the serum creatinine levels, FENa, and 
creatinine clearance in rats treated exclusively 
with either Mn (II)-EGTA (2 mg/kg) or Mn (II)-
EHPG (4 mg/kg) as compared to the control 
group. Co-administration of paraquat (10 mg/kg) 
and Mn (II)-EGTA (2 mg/kg) did not protect the 
rats against paraquat-induced AKI; as the 
increase in serum creatinine levels and FENa, and 
the reduction in creatinine clearance seen in 
these rats were statistically similar to the paraquat 
only treated group (P>0.05). However, Mn (II)-
EHPG (4 mg/kg) reduced the increases in serum 
creatinine levels and FENa, and increased the 
reduction in creatinine clearance caused by 10 
mg/kg paraquat to almost baseline control levels 
(P<0.05) (Figure 2 (A-C).  
 
As Mn (II)-EHPG (4 mg/kg) completely protected 
the rats against the nephrotoxic effect of 10 mg/kg 
paraquat, its ability to provide similar protection 
against the nephrotoxic effect of 50 mg/kg 
paraquat was further investigated. Unlike the 
control and Mn (II)-EHPG only treated groups; 
proteinuria, haematuria, glycosuria, and spastic 
paralysis of the hind limbs with moderate-severe 
respiratory distress were noted in rats treated 
exclusively with 50 mg/kg paraquat. These 
physical manifestations and urinalysis profile were 
also observed though to a lesser degree, in the 
paraquat (50 mg/kg) plus Mn (II)-EHPG (4 mg/kg) 
treated group. In addition, administration of 50 
mg/kg dose of paraquat significantly increased 
the serum creatinine levels and FENa by 3 and 12 
fold respectively with a significant reduction in 
creatinine clearance by 98 % when compared to 
the control group (P<0.05; Figure 3 (A-C). In the 
presence of Mn (II)-EHPG (4 mg/kg) the paraquat 
-mediated increase serum creatinine and FENa 
were significantly reduced by 64 and 49 % 
respectively (P<0.05; Figures 3A and B). 
However, this was not accompanied by any 
significant increase in creatinine clearance 
(P>0.05; Figure 3C). As speculated, Mn (II)-
EHPG (4 mg/kg) on its own did not alter the 
serum creatinine levels, FENa, and creatinine 
clearance to any significant extent when 
compared to the control group (P>0.05; Figure 3 
(A-C)).  
 
































Figure 1A: Serum Creatinine Levels 
 





































Figure 1B: Fractional Excretion of Sodium 
 





































Figure 1C: Creatinine Clearance 
 
Figure 1(A-C): Effects of paraquat on (A) Serum creatinine 
levels, (B) Fractional excretion of sodium and (C) Creatinine 
clearance. Rats were intraperitoneally treated with normal 
saline only or paraquat dissolved in normal saline (2.5-100 
mg/kg) N=8 for each subgroup). *P < 0.05 vs. control group. 
 























































































































































































































































Figure 2C: Creatinine Clearance 
Figure 2(A-C): Effects of Mn (II)-EGTA and Mn (II)-EHPG on  
paraquat-induced increase in serum creatinine levels (A), and  
fractional excretion of sodium (B) and paraquat-mediated 
reduction in creatinine clearance (C). Rats were treated 
intraperitoneally with normal saline only, Mn (II)-EGTA only (2 
mg/kg), Mn (II)-EHPG only (4 mg/kg) or paraquat dissolved in 
normal saline (10 mg/kg) in the presence or absence Mn (II)-
EGTA or Mn (II)-EHPG (N=6 for each subgroup). *P< 0.05 vs. 
paraquat only treated group and ●P< 0.05 vs. control group  






























































































































































































Figure 3C: Creatinine Clearance 
 
Figure 3(A-C): Effects of Mn (II)-EHPG on paraquat-induced  
increase in serum creatinine levels (A), and fractional 
excretion of sodium (B) and paraquat-mediated reduction in 
creatinine clearance (C). Rats were treated intraperitoneally 
with normal saline only, Mn (II)-EHPG only (4 mg/kg) or 
paraquat dissolved in normal saline (50 mg/kg) in the 
presence or absence Mn (II)-EHPG (N=6 for each subgroup). 
 *P< 0.05 vs. control group (rats treated with normal saline 
only) and ●P < 0.05 vs. paraquat only treated group. 
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DISCUSSION 
The results of the in vivo studies confirm the 
nephrotoxic effect of paraquat in addition to its 
cytotoxic action on other tissues particularly the 
pulmonary and neuromuscular tissues. As with 
the in vitro findings the nephrotoxic effects of 
paraquat was noted to be both dose and time 
dependent (Samai et al., 2007; 2008). 
Specifically, paraquat produces a dose dependent 
AKI as evidenced by a progressive increase in 
serum creatinine levels with increase in dose. 
Paraquat -mediated AKI has been shown to be 
due to a combination of pre-renal factors such as 
hypovolaemia and hypotension and/or renal 
factors such as acute tubular necrosis (ATN) 
(Beebeejaun et al., 1971; Harsanyi et al., 1987). 
  
Severe dehydration secondary to polyuria/diuresis 
and coupled with the inability of the rats to drink 
due too ill health as seen in the current study, 
may have led to hypovolaemia and severe 
hypotension with a subsequent reduction in renal 
perfusion; thereby causing renal ischaemia. Renal 
ischaemia increases serum renin levels and 
hyperreninaemia has been demonstrated in dogs 
after toxic administration of paraquat (25 mg/kg) 
(Giri et al., 1982). Reduction in renal blood flow 
also reduces glomerular filtration rate (GFR); and 
a reduction in GFR by paraquat has been 
previously documented by Vaziri et al., (1979) 
and Prashad et al., (1981). This has been 
confirmed in the current study as evidenced by a 
significant reduction in creatinine clearance, 
which was used as an indicator of GFR.  
 
In addition, ATN particularly of the proximal tubule 
(PT) has been showed on histopathological 
examinations of human kidneys taken from 
paraquat-poisoned patients (Beebeeja et al., 
1971; Onyeama and Oehme, 1984). Although 
histopathological examination of the paraquat 
poisoned kidneys were not performed in the 
current study for physical evidence of ATN, 
intrinsic renal failure was confirmed biochemically 
by the measurement of the FENa. Fractional 
excretion of sodium between 1-3 % is usually 
normal and values less than 1 % or greater 3 % is 
suggestive of pre- or intrinsic- renal failure 
respectively. Intrinsic renal failure, possibly ATN 
has been confirmed biochemically in the current 
study as the values for the FENa were noted to be 
greater than 3 %.  
 
Moreover, several PT dysfunctional parameters 
including diuresis, proteinuria, and glycosuria, 
with a concurrent increase in renal leakage of 
sodium, potassium and chloride ions have been 
shown in rats (Lock and Ishmeal, 1979), dogs 
(Giri et al., 1982; Nagata et al., 1992) and 
monkeys (Purser and Rose, 1979) following 
paraquat treatment. Additionally, other PT 
dysfunctional parameters, such as impaired 
phosphate and uric acid transport (Vaziri et al., 
1979), lactic aciduria, 3-D-hydroxybutyric aciduria 
and a reduction in the excretion of citrate and 
succinate (Bairaktari et al., 1998) have been 
noted in paraquat poisoned patients. 
Furthermore, abnormal morphological findings 
have been demonstrated in the PT of rats (Lock 
and Ishmeal, 1979), rabbits (Yonemitsu, 1986), 
and dogs (Giri et al., 1982; Nagata et al., 1992) 
exposed to paraquat. Proximal tubule damage 
has been confirmed biochemically in the current 
study as evidenced by polyuria/diuresis, 
proteinuria, glycosuria and increase FENa.  
 
Apart from its nephrotoxic effect, the highest dose 
of paraquat (100 mg/kg) examined in vivo also 
produced severe respiratory distress as 
evidenced by intercoastal recession, nasal flaring 
with a very rapid and shallow respiration; and 
spastic paralysis of the hind limbs within 24 hours. 
These manifestations were noted, though to a 
limited extent, in rats treated with 50 mg/kg dose 
of paraquat after 48 hours of treatment; but were 
not apparent in the 2.5-10 mg/kg paraquat treated 
rats. The spastic paralysis of the hind limbs 
observed in these rats could be either locally or 
centrally mediated. It is possible that paraquat 
may have produced succinylcholine-like action on 
the neuromuscular endplate. However, in view of 
reports that paraquat induces Parkinson’s disease 
(Melchiorri et al., 1998; Vogt et al., 1998; Chun et 
al., 2001); it is more likely that paraquat may have 
increased the peripheral cholinergic action.  
 
 Although none of the rats in the current study 
died during the experimental period, pulmonary 
toxicity such as pulmonary fibrosis (Uhal et al., 
1995) and pneumomediastinum (Sittipunt, 2005) 
which has a poor prognosis with a mortality rate 
of almost 100 % (Im et al., 1991); has been widely 
documented to be responsible for most of the 
deaths associated with paraquat poisoning. In the 
presence of ARF, plasma and tissue paraquat 
levels including the lung tissues increase by 5-fold 
(Hawksworth, et al., 1981). Acute renal failure is a 
life threatening illness with a high mortality 
despite advances in supportive treatment. 
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In general, uraemia secondary to ARF has been 
documented to be associated with increased 
oxidative stress (Ichikawa et al., 1994; Witko-
Sarsat et al., 1996). In addition, reduced 
antioxidant levels have been demonstrated in 
uraemic patients on haemodialysis or peritoneal 
dialysis (Epperlein et al., 1998). Moreover several 
experimental animal models and in vitro studies 
have established a role for reactive oxygen 
species and the therapeutic potential for free 
radical scavengers in renal dysfunction. 
 
The safe profile of Mn (II) and Cu (II) complexes 
of EGTA and EHPG will allow investigations of 
these complexes in vivo to assess their efficacy 
against many pathological conditions involving 
ROS generation and oxidative stress (Samai et 
al., 2008). However, some care may need to be 
taken when Cu (II) complexes are utilised in view 
of a report that Cu (II) derived from Cu/Zn-SOD 
may facilitate oxidative stress in the presence of 
glutathione (Paller and Eaton, 1995). Both EGTA 
and EHPG have the advantage that they have 
already been used in biological systems for their 
respective chelation and imaging properties and 
therefore their clinical toxicity profiles are already 
known. In addition, their long-term effects and 
stability in biological systems have been 
demonstrated (Fisher, et al., 2004b).  
 
Furthermore, SOD and catalase activities of Mn 
(II), Cu (II) and Fe (III) complexes of another 
chelating agent, EDTA, have previously been 
reported (Fisher et al., 2004a) and subsequently, 
EDTA itself has been reported to protect against 
ischaemic renal injury via modulation of 
endothelial nitric oxide synthase (eNOS) and NO 
production (Foglieni et al., 2006). Since Mn (II) 
complexes of EGTA and EHPG have been 
previously demonstrated to be reno-protective 
and safe in vitro (Samai et al., 2008),  it was 
anticipated that these complexes may provide 
similar benefits in vivo, a hypothesis which was 
further tested in a rodent model of paraquat -
induced AKI. 
 
In the rodent model of paraquat -induced AKI 
characterised in the current study, Mn (II)-EGTA 
at the dose examined (2 mg/kg) was found to be 
ineffective in protecting the subgroup of rats 
exposed to 10 mg/kg paraquat against the 
paraquat -mediated AKI. On the other hand, Mn 
(II)-EHPG (4 mg/kg) provided absolute protection 
against the paraquat-induced AKI in the subgroup 
of rats exposed to 10 mg/kg paraquat; as 
evidenced by a complete reversal of the serum 
creatinine, FENa and creatinine clearance to the 
baseline control values. This illustrates the 
reversible nature of paraquat-induced AKI; as 
paraquat -induced ARF is reversible if patients 
ingest less than 40 mg/kg paraquat (Vale et al., 
1987). Although similar dose of Mn (II)-EHPG (4 
mg/kg) significantly reduced the paraquat -
induced AKI in the subgroup of rats treated with 
50 mg/kg dose of paraquat, it did not provide 
absolute protection.  
 
The inability of Mn (II)-EGTA to provide any 
protection against paraquat-induced AKI in the 10 
mg/kg paraquat treated subgroup of rats, could be 
possibly related, in part, to the dose employed. 
Although doses greater than 2 mg/kg Mn (II)-
EGTA were not examined as 2 mg/kg was the 
highest achievable dose; it is however anticipated 
that doses greater than or equal to 4 mg/kg could 
provide similar protection as that seen with 4 
mg/kg Mn (II)-EHPG. As with the in vitro findings 
(Samai et al., 2008), Mn (II) complexes of EGTA 
and EHPG at the doses examined were not 
biochemically toxic to the renal system and 
particularly the kidney cells in vivo. 
 
CONCLUSION 
The novel SODm Mn (II)-EHPG is beneficial in 
the reduction of paraquat -mediated AKI in a 
rodent model. Since the clinical toxicity profiles of 
EHPG are already known, this novel SODm could 
be beneficial in attenuating disease conditions 
involving ROS generation. 
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